Abstract T P220: Primate Model of Intracranial Aneurysm to Examine the Effect of Drugs on Aneurysm Growth
Current problem of intracranial aneurysm treatment is a lack of medical therapy for patients without surgical indication. Considered with the high incidence of aneurysm and the devastating outcome by subarachnoid hemorrhage after rupture, the development of a novel therapeutic drug to prevent the enlargement or rupture of aneurysms should be established. To examine the effect of drugs on enlargement of aneurysm in vivo, we established the primate model of intracranial aneurysm. In this model, female Macaca fascicularis was used and aneurysms were induced at bifurcation sites of intracranial arteries by the ligation of one side of carotid artery and bilateral oophorectomy accompanied with the systemic hypertension by salt-overloading. In this model, unlike rodent model of aneurysms, we can keep track of aneurysm formation and enlargement by sequential MRA examinations in same animals without sacrificing them. Indeed, we could detect the induction of intracranial aneurysms defined by the saccular lesion in MRA studies in 43% (3/7) of animals subjected to models. Histopathologically, we confirmed that, all primates examined developed aneurysmal changes evidenced by disrupted elastic lamina and degeneration of media at bifurcation sites of intracranial arteries during 26 months of follow-up. We, further, successfully followed up the therapeutic effect of the drug on enlargement of aneurysms induced in this model. In conclusion, primate models and sequential following up of induced aneurysms by MRA is a powerful tool to assess the effect of drugs on aneurysms and contribute greatly to develop medical therapy for intracranial aneurysms.
Author Disclosures: K. Tsuji: None. M. Saito: None. T. Yokoi: None. T. Aoki: None. K. Nozaki: None.
- © 2015 by American Heart Association, Inc.